Shoham, Portugal

Gerardo Lederkremer

This inventor holds 1 USPTO granted patent. Top assignee: Prilenia Neurotherapeutics Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gerardo Lederkremer. Retrieved from https://idiyas.com/inventor/gerardo-lederkremer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gerardo Lederkremer: Innovator in Neurotherapeutics

Introduction

Gerardo Lederkremer is a prominent inventor based in Shoham, PT. He has made significant contributions to the field of neurotherapeutics, particularly in the treatment of mitochondrial-associated diseases and disorders.

Latest Patents

Lederkremer holds a patent for "Pridopidine for the Treatment of Mitochondrial-Associated Diseases and Disorders and Endoplasmic Reticulum (ER) Stress." This innovative approach aims to address critical health issues related to mitochondrial dysfunction.

Career Highlights

Gerardo Lederkremer is associated with Prilenia Neurotherapeutics Ltd., where he applies his expertise to advance therapeutic solutions. His work focuses on developing treatments that can significantly improve patient outcomes in neurodegenerative conditions.

Collaborations

He has collaborated with notable professionals in the field, including Michael Hayden and Michal Geva. These partnerships enhance the research and development efforts at Prilenia Neurotherapeutics Ltd.

Conclusion

Gerardo Lederkremer's contributions to neurotherapeutics exemplify the impact of innovative thinking in medicine. His work continues to pave the way for advancements in treating complex diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…